Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

NCT07639138 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Lenalidomide
DRUG: Targeted Therapy
DRUG: Immune Checkpoint Inhibitors

Sponsor

Shunda Du